Alto Pharmacy Holdings, Inc. (FKA: ScriptDash, Inc.; AKA: Alto Pharmacy) operates a distributor of medication and applies innovative technology to provide a patient-centric pharmacy and offer patients a convenient pharmacy experience and accessible healthcare. It is also a component in the Prime Unicorn Index benchmark, the standard bearer for private markets benchmarking.
In January 2022, Alto Pharmacy raised $200mm in a Series E Preferred round led by SoftBank, with participation from 10X Capital, Expanding Capital, and others which valued the company at roughly $1.3 billion on a post-money valuation basis at a preferred price per share of $15.46. On June 26, 2023, it authorized a Series F Preferred round at $6.1432 per share, dropping the company’s valuation to roughly $531mm. This jeopardizes the company’s status as a unicorn and puts it at risk of being removed from the Prime Unicorn Index at the end of the next quarter.
The Prime Unicorn Index is the standard for Private Company benchmarking. For more granular data, charting analytics, trends, or to review the actual documents, get started here.